Quantitative evaluation of sphingomyelin and glucosylceramide using matrix-assisted laser desorption ionization time-of-flight mass spectrometry with sphingosylphosphorylcholine as an internal standard. Practical application to tissues from patients with Niemann-Pick disease types A and C, and Gaucher disease.
Niemann-Pick disease types A and C, and Gaucher disease are glycolipid storage disorders characterized by the systemic deposition of glycosphingolipids, i.e., sphingomyelin in Niemann-Pick disease types A and C tissues and glucosylceramide in Gaucher disease ones, respectively. Using matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF/MS), we analyzed the sphingolipids in liver and spleen specimens from patients with Niemann-Pick disease types A and C, and Gaucher disease. Crude lipids were extracted from tissue containing 5mg protein with chloroform and methanol. After mild alkaline treatment of the crude lipids, a sphingolipid fraction was prepared and analyzed by MALDI-TOF/MS. The results were as follows: (a) ion peaks with m/z values corresponding to different sphingomyelin and ceramide monohexoside (CMH) species were clearly detected. (b) With sphingosylphosphorylcholine as the internal standard for quantification of sphingomyelin and CMH, the relative peak heights of sphingomyelin and CMH were calculated and plotted versus their contents. The relative peak heights of sphingomyelin and CMH showed linearity between 50 and 1500 ng sphingomyelin content, and between 5 and 150 ng CMH content, respectively. (c) Quantitative analysis revealed the accumulation of sphingomyelin in the liver and spleen specimens from the patients with Niemann-Pick disease types A and C. Striking accumulation of CMH was also detected in the liver and spleen specimens from the patients with Gaucher disease. This investigation indicated that accumulated sphingomyelin and CMH in small amounts of tissues from sphingolipidosis patients can be detected quantatively with the MALDI-TOF/MS method. This method will be useful not only for the diagnosis but also for biochemical pathophysiology evaluation of patients with various sphingolipidosis.
Fujiwaki
Takehisa
T
Department of Pediatrics, Shimane University School of Medicine, 89-1 Enya-cho, Izumo 693-8501, Japan. take-fujiwaki@k7.dion.ne.jp
Tasaka
Masaru
M
Yamaguchi
Seiji
S
D002675:Child, Preschool; D005776:Gaucher Disease / Q000175:diagnosis* / Q000378:metabolism; D005963:Glucosylceramides / Q000032:analysis* / Q000737:chemistry; D006801:Humans; D008099:Liver / Q000737:chemistry; D009542:Niemann-Pick Diseases / Q000175:diagnosis* / Q000378:metabolism; D010767:Phosphorylcholine / Q000031:analogs & derivatives / Q000032:analysis; D012015:Reference Standards; D019032:Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization / Q000379:methods*; D013109:Sphingomyelins / Q000032:analysis* / Q000737:chemistry; D013110:Sphingosine / Q000031:analogs & derivatives / Q000032:analysis; D013154:Spleen / Q000737:chemistry
D005963:Glucosylceramides; D013109:Sphingomyelins; C005356:sphingosine phosphorylcholine; D010767:Phosphorylcholine; D013110:Sphingosine